No Data
No Data
Buy Rating Affirmed for Plus Therapeutics Amid Strong Clinical Results and Positive Financial Outlook
Plus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials
Express News | HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Plus Therapeutics Analyst Ratings
No Data